CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

MSB11456Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug550 COVID-19 Swab Wiki 1.00
drug962 EU-approved RoActemra Wiki 1.00

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D001172 Arthritis, Rheumatoid NIH 0.35
D001168 Arthritis NIH 0.28

Correlated HPO Terms (2)

Name (Synonyms) Correlation
HP:0001370 Rheumatoid arthritis HPO 0.35
HP:0001369 Arthritis HPO 0.28

There is one clinical trial.

Clinical Trials

1 A Randomized, Double-Blind, Multiple-Dose, Parallel-Group, Two-Arm Study to Evaluate the Efficacy, Safety and Immunogenicity of MSB11456 Compared to European Union-approved RoActemra® in Patients With Moderately to Severely Active Rheumatoid Arthritis (APTURA I Study)

The purpose of the study is to compare the efficacy, safety and immunogenicity of MSB11456 and EU approved RoActemra® in participants with moderately to severely active rheumatoid arthritis. Participants will be randomized at the beginning of the Core Treatment Period (Baseline to Week 24) to receive either MSB11456 or EU approved RoActemra® once a week (QW). At the beginning of the Extended Treatment Period (Week 24 to Week 52), participants who received RoActemra® will be re-randomized to either continue receiving RoActemra® QW or switch to receive MSB11456 QW.

NCT04512001 Rheumatoid Arthritis Drug: MSB11456 Drug: EU-approved RoActemra
MeSH:Arthritis Arthritis, Rheumatoid
HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

Primary Outcomes

Measure: Change from Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR)

Time: Baseline; Week 24

Secondary Outcomes

Measure: Change from Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR)

Time: Baseline; Week 52

Measure: Number of Participants with 20% Improvement in American College of Rheumatology (ACR20) Response

Time: Week 24

Measure: Number of Participants who Experienced One or More Treatment-Emergent Adverse Event (TEAE)

Time: Baseline to end of study, up to Week 63

Measure: Number of Participants who Experienced One or More Serious Adverse Event (SAE)

Time: Baseline to end of study, up to Week 63

Measure: Number of Participants with Positive Anti-Drug Antibodies (ADAs)

Time: Week 2; Week 55

Measure: Anti-Drug Antibodies (ADAs) Titer Levels

Time: Week 2; Week 55

Measure: Number of Participants with Confirmed Neutralizing Antibodies (NAb)

Time: Week 2; Week 55

Related HPO nodes (Using clinical trials)

HP:0001369: Arthritis
Genes 263
CCN6 IL2RA NFKBIL1 LBR SPTB BLNK TRAPPC2 EPB42 MVK CD79A IL36RN COMP STAT3 IL2RB TGFB3 MEFV IL12A-AS1 CASP10 MLX MMP13 SLCO2A1 COL2A1 COL2A1 ASAH1 IGHM COL2A1 APOE HNF4A COL2A1 ADA2 PTPN22 MMP14 NOD2 CD247 BTK SCARB2 COL2A1 GLA UMOD CCR1 COL11A2 LRBA CCR6 COMP EXT1 IL6 RREB1 KLRC4 COL11A1 PTPN22 PSTPIP1 HNF1B SAMHD1 HLA-C COL11A2 LRP6 GPR101 COL2A1 RAG1 KIF7 DCLRE1C NOD2 CTLA4 NLRP3 HPRT1 ABCG8 HGD MMP13 HLA-DRB1 NLRP3 SH3KBP1 SLC37A4 TF CCN6 ZNF687 GJB2 IL2RA PFKM AIP FASLG TREX1 HLA-B MATN3 ASPN TNFRSF1A C4A COL2A1 MYH14 UBAC2 FAS ARVCF ACP5 EXT2 PRG4 AEBP1 MTHFD1 ANKRD55 PTPN22 TFR2 GCH1 GJB6 COL9A1 COL11A2 PTPN22 SPP1 RNASEH2B TRAPPC2 OCRL TREX1 LRRC8A GBA COL1A1 LMX1B ACAN GP1BB TLR4 ANK1 COMP UFD1 SLC12A3 NLRP3 FAS HGD IL12A SEC61A1 PHEX COPA HPGD IRF5 FCGR2B TRPV4 PSMB9 WIPF1 CTLA4 CAV1 MVK HLA-DRB1 ATP7B MUC1 COL9A1 ACAN ATP7B EPCAM DNASE1L3 CLCNKB LMNA MMP2 IL10 IL12B RASGRP1 PTPN2 COMT COL2A1 STAT4 SLC37A4 GNAS MIF HLA-DRB1 WAS STAT4 RNF168 CLCN7 JMJD1C IL23R MEFV G6PC CFI ERAP1 F8 PSTPIP1 GHR HLA-B HIRA PRPS1 ADAR DNAJB11 MEFV PTPN2 IL10 ANKH IFIH1 STAT4 COL5A1 FRZB HPGD KIF22 TBX1 CIITA CD79B IGLL1 IRAK1 IL2RB MATN3 COL9A2 COL9A3 TNFRSF11B COMP HLA-B STAT4 PADI4 MATN3 HJV COL2A1 SMAD3 F9 TRPS1 UFSP2 RAG2 COL1A1 MEFV COL5A1 ANKRD55 SLC40A1 SLC4A1 SPTA1 FBN1 BTK RNASEH2C DNASE1 CANT1 TBX1 PHEX CD247 TCF3 PSMB4 PIK3R1 AGA CD244 COL5A2 LEMD3 FGFR3 RNASEH2A ACAN HPRT1 ANKH SEC24C GDF5 SLC22A4 UMOD HPRT1 TRPV4 HPGD BTK FAS COL9A3 UFSP2 ZMPSTE24 PTPN22 LACC1 HPRT1 NLRP3 HNF1B HOXD10 PRKCD SLC26A2 COL9A2 SMAD3 FCGR2A CCN2 CLCN7 COL3A1 ASAH1 NLRP12
Protein Mutations 4
A147T N363S R620W V600E
SNP 10
rs2246704 rs2853884 rs35705950 rs3747158 rs3790515 rs3828057 rs4820059 rs7291050 rs933226 rs9826
HP:0005764: Polyarticular arthritis
Genes 13
ANKRD55 CD247 STAT4 NOD2 NLRP1 IL2RA DMP1 ENPP1 TNFAIP3 MEFV IL2RB PTPN2 PTPN22
Protein Mutations 0
SNP 0
HP:0001370: Rheumatoid arthritis
Genes 28
ANKRD55 IL2RA NFKBIL1 CD247 GCH1 STAT4 PADI4 SLC22A4 IL2RA ANKRD55 IL6 PTPN2 IL2RB IL10 STAT4 HLA-DRB1 PTPN22 PTPN22 LACC1 ACP5 DCLRE1C CIITA CD247 PTPN2 MIF CD244 IL2RB PTPN22
Protein Mutations 4
A147T N363S R620W V600E
SNP 10
rs2246704 rs2853884 rs35705950 rs3747158 rs3790515 rs3828057 rs4820059 rs7291050 rs933226 rs9826